Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324426 · ClinicalTrials.gov registry record · Phase 1
CNS Uptake of Intranasal Glutathione
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02324426 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 15 participants.
The verdict
NCT02324426, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Excessive free radical formation and depletion of the brain's primary antioxidant, glutathione, are established components of Parkinson's disease (PD) pathophysiology. While there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some preliminary evidence to suggest the use of GSH can lead to symptomatic improvement, obstacles surrounding currently employed delivery methods have hindered the clinical utility of this therapy. Intranasal GSH, (in)GSH, is a novel method of glutathione augmentation. The aim of this study is to evaluate whether 200 mg of (in)GSH results in measurable changes in brain glutathione concentrations, as measured by magnetic resonance spectroscopy (MRS) in 15 individuals with PD.
Interventions
- DRUG Reduced Glutathione
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02324426
The ClinicalTrials.gov registry entry for NCT02324426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reduced Glutathione is the first listed.
NCT02324426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02324426 about?
NCT02324426 is a clinical study titled "CNS Uptake of Intranasal Glutathione". Excessive free radical formation and depletion of the brain's primary antioxidant, glutathione, are established components of Parkinson's disease (PD) pathophysiology. While there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some preliminary evidence to suggest t...
What is the current status of trial NCT02324426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-12. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02324426?
The interventions under investigation include: Reduced Glutathione (DRUG).
Who is sponsoring clinical trial NCT02324426?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.